Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021

Learned, Christine; Alsukait, Sara; Deverapalli, Sandhya; Elliott, Erika; Moody, Katherine; Sobell, Jeffrey M.; Konnikov, Nellie; Ortega, Melissa; Rosmarin, David

doi:10.1016/j.jdin.2022.03.010

Cited by 3 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this respect, the BBs can flare the preexisting PsD in one hand, and induce the de novo PsD in naïve individuals on the other hand. For instance, metoprolol, as a β1 selective blocker-which is one of the widely prescribed BBs in the U.S.-there are 97 reports highlighting that Ps is being the most cutaneous adverse events following metoprolol administration based on US Food and Drug Administration (FDA)'s adverse event reporting system 80 . Beyond the exuberant pre-inflammatory responses, the modification of intracellular calcium (Ca 2+ ) levels, keratinocyte proliferation, and granulocyte function by targeting cyclic adenosine monophosphate (cAMP) pathways are indicated as the underlying mechanisms involved in the BBs-induced psoriasis at the cellular level 81 .…”

Section: Beta Blockers (Bbs)mentioning

confidence: 99%

See 1 more Smart Citation

Causes of Autoimmune Psoriasis and Associated Cardiovascular Disease: Roles of Human Endogenous Retroviruses and Antihypertensive Drugs—A Systematic Review and Meta-analysis

Rezabakhsh,

Manjili,

Hosseinifard

et al. 2023

Preprint

View full text Add to dashboard Cite

Current treatments are ineffective to cure or prevent occurrences of autoimmune psoriasis and psoriatic cardiovascular disease/CVD. Psoriasis is associated with deregulated expressions of human endogenous retroviruses (ERVs) variants. ERV transcripts and proteins are detected in lesioned biopsies—without assembled viral particles—in addition to antibody and T-cell responses against ERV-K dUTPase. In persons living with HIV-1, manifestations of psoriasis are exacerbated variably. These may depend on multiple factors, differences in ERVs expressions, subtypes of HIV-1, and/or epigenetics. This article represents a quantitative risk assessment and meta-analysis approach with an attempt to assess causality. We surmise that mutated ERVs trigger aberrant proliferation and differentiation of keratinocytes, which in turn induce proinflammatory polarization. Independent risk factors and/or covariates with a range of relative risk/RR ratios appear to significantly impact the development of autoimmune psoriasis or immune intolerance, plausibly through ERVs genes activity. Given the antihypertensive drug’s potential in psoriasis development, a probable role in promising either ERVs activation or perturbations in epigenetic factors is questionable. Although the correlational nature of the data based on RR ratios prevents making robust conclusions, we reckon that the likelihood of attributable risk factors for certain antihypertensive drugs may stem from their pleiotropic effects or potentials for inducing ERV-mediated dysregulation of keratinocytes and/or endothelial cells. These findings expand our knowledge regarding ERV activations and HIV-1, antihypertensive drugs use, and incidents of psoriatic disease, and call for exploring cell-specific therapies aimed at blocking or reversing mutated ERVs gene activity toward attaining stable remissions in psoriasis and associated CVD.

show abstract

Section: Beta Blockers (Bbs)mentioning

confidence: 99%

“…80, df= 3, I 2 = 90.85). Moreover, the risk of PsD incident in the intervention group is 57% higher than the control group [pooled RR =1.57, 95% CI (1.89-1.95), z-value = 8.07, p-value < 0.001].…”

mentioning

confidence: 94%

Causes of Autoimmune Psoriasis and Associated Cardiovascular Disease: Roles of Human Endogenous Retroviruses and Antihypertensive Drugs—A Systematic Review and Meta-analysis

Rezabakhsh,

Manjili,

Hosseinifard

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Because of the discrepancy between the low rates of adverse events in psoriatic patients on systemic glucocorticosteroids and their wide use in this patient population, some argue against the limitation of these agents in psoriasis [ 10 , 12 , 13 ]. Interestingly, a report from the US Food and Drug Administration for the period 2016–2021 determines prednisone as the most common drug related to psoriasis as an adverse event of drug therapy [ 14 ]. Systemic glucocorticosteroids have the potential to exacerbate plaque psoriasis and induce severe forms of the disease but these drugs are indispensable in treating certain comorbidities of psoriasis patients.…”

mentioning

confidence: 99%